Article tools
Author information
Published in Volume 97, Issue 2 (January 15,1996)
J. Clin. Invest. 97(2): 331-338 (1996). doi:10.1172/JCI118420.
Copyright © 1996, The American Society for Clinical Investigation.

Research Article

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.

I A Heijnen, M J van Vugt, N A Fanger, R F Graziano, T P de Wit, F M Hofhuis, P M Guyre, P J Capel, J S Verbeek and J G van de Winkel

Department of Immunology, University Hospital Utrecht, The Netherlands.

Published January 15, 1996

Besides their phagocytic effector functions, myeloid cells have an essential role as accessory cells in the induction of optimal humoral immune responses by presenting captured antigens and activating lymphocytes. Antigen presentation by human monocytes was recently found to be enhanced in vitro through the high-affinity Fc receptor for IgG (Fc gamma RI; CD64), which is exclusively present on myeloid cells. To evaluate a comparable role of Fc gamma RI in antigen presentation in vivo, we generated human Fc gamma RI transgenic mice. Under control of its endogenous promoter, human Fc gamma RI was selectively expressed on murine myeloid cells at physiological expression levels. As in humans, expression was properly regulated by the cytokines IFN-gamma, G-CSF, IL-4, and IL-10, and was up-regulated during inflammation. The human receptor expressed by murine macrophages bound monomeric human IgG and mediated particle phagocytosis and IgG complex internalization. To evaluate whether specific targeting of antigens to Fc gamma RI can induce enhanced antibody responses, mice were immunized with an anti-human Fc gamma RI antibody containing antigenic determinants. Transgenic mice produced antigen-specific antibody responses with high IgG1 titers and substantial IgG2a and IgG2b responses. These data demonstrate that human Fc gamma RI on myeloid cells is highly active in mediating enhanced antigen presentation in vivo, and show that anti-Fc gamma RI mAbs are promising vaccine adjuvants.

This article Copyright © 1996, The American Society for Clinical Investigation.

Articles that cite
this article:

Enhanced transduction of dendritic cells by FcγRI-targeted adenovirus vectors
Ramil Sapinoro, Casey A. Maguire, Angela Burgess, Stephen Dewhurst
J Gene Med 9(12):1033. [CrossRef]

Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens
Edmund J. Gosselin, Constantine Bitsaktsis, Ying Li, Bibiana V. Iglesias
Arch Immunol Ther Exp 57(5):311. [CrossRef]

Delivery of Chlamydia vaccines
Joseph Igietseme, Francis Eko, Qing He, Claudiu Bandea, Werner Lubitz, Adolfo Garcia-sastre, Carolyn Black
Expert Opin Drug Deliv 2(3):549. [CrossRef]

Bispecific antibodies for the treatment of tumours and infectious diseases
Donald L Drakeman, Michael W Fanger, Paul K Wallace
Expert Opin Invest Drugs 6(9):1169. [CrossRef]

Neutrophils in antibody-based immunotherapy of cancer
Marjolein Van egmond
ebot 8(1):83. [CrossRef]

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral
Vasso Apostolopoulos, Carla Osinski, Ian F.C. Mckenzie
Nat Med 4(3):315. [CrossRef]

The neutrophil: one of the cellular targets of interleukin-10
M. A. Cassatella
IJ Clinical & Laboratory Research 28(3):148. [CrossRef]

Immune complex–mediated antigen presentation induces tumor immunity
Khadija Rafiq, Amy Bergtold, Raphael Clynes
J Clin Invest 110(1):71. [CrossRef]

Surfactant protein D/anti-Fc receptor bifunctional proteins as a tool to enhance host defence
Esther CW Breij, Joseph J Batenburg
ebot 8(4):409. [CrossRef]

IFN-γ induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells
Peter Uciechowski, Mario Schwarz, J. Engelbert Gessner, Reinhold E. Schmidt, Klaus Resch, Heinfried H. Radeke
Eur J Immunol 28(9):2928. [CrossRef]

IgG3-Mediated Enhancement of the Antibody Response is Normal in FcgammaRI-Deficient Mice
F. Hjelm, F. Carlsson, S. Verbeek, B. Heyman
Scand J Immunol 62(5):453. [CrossRef]

Monocyte CD64 or CD89 targeting by surfactant protein D/anti-Fc receptor mediates bacterial uptake
Paul J. Tacken, Joseph J. Batenburg
IMMUNOL 117(4):494. [CrossRef]

Fc RECEPTOR BIOLOGY
Marc Daeron
annu rev immunol 15(1):203. [CrossRef]

Cytotoxicity of Anti-CD64-Ricin A Chain Immunotoxin Against Human Acute Myeloid Leukemia Cells In Vitro and in SCID Mice
R.K. Zhong, J.G.J. Van de winkel, T. Thepen, L.D. Schultz, E.D. Ball
j hematother stem cell res 10(1):95. [CrossRef]

C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI)
Katherine B. Bodman-smith, Alirio J. Melendez, Ian Campbell, Patrick T. Harrison, Janet M. Allen, John G. Raynes
IMMUNOL 107(2):252. [CrossRef]

Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 - a humanized human leucocyte antigen DR antibody
Bernhard Stockmeyer, Martin Schiller, Roland Repp, Hanns-Martin Lorenz, Joachim R. Kalden, Martin Gramatzki, Thomas Valerius
Br J Haematol 118(4):959. [CrossRef]

Contemporary approaches to designing and evaluating vaccines against Chlamydia
Joseph U Igietseme, Francis O Eko, Carolyn M Black
Expert Rev Vaccines 2(1):129. [CrossRef]

Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens
Joseph U Igietseme, Francis O Eko, Qing He, Carolyn M Black
Expert Rev Vaccines 3(1):23. [CrossRef]

Regulation of B-Cell Activation by Complement Receptors and Fc Receptors
Claus Henrik Nielsen, Robert Graham Quinton Leslie
Transfus Med Hemother 32(6):339. [CrossRef]

Regulation of murine hypersensitive responses by Fc receptors.
Toshiyuki Takai, Masao Ono, Azusa Ujike, Takae Yuasa
Allergology Int 47(2):75. [CrossRef]


Giuseppe Sconocchia, Nella Cococcetta, Laura Campagnano, Sergio Amadori, Beniamino Iorio, Vittorio Boffo, Vincenzo Ferdinandi, Ilaria Principe, Domenico Adorno, Carlo Casciani
J Immunother 24(4):374. [CrossRef]

Direct targeting of genetically modified tumour cells to FcgammaRI triggers potent tumour cytotoxicity
Lisette Bevaart, Joel Goldstein, Laura Vitale, Christina Russoniello, John Treml, Jun Zhang, Robert F. Graziano, Jeanette H. W. Leusen, Jan G. J. Winkel, Tibor Keler
Br J Haematol 132(3):317. [CrossRef]

Combination vaccines: design strategies and future trends
Joseph U Igietseme, Francis O Eko, Qing He, Carolyn M Black
Expert Rev Vaccines 5(6):739. [CrossRef]

A novel Fcγ receptor ligand augments humoral responses by targeting antigen to Fcγ receptors
Mark A. Jensen, Barry G. W. Arnason, David M. White
Eur J Immunol 37(4):1139. [CrossRef]

Prostaglandin E2 modulates dendritic cell function during chlamydial genital infection
Wei Liu, Kathleen Ann Kelly
IMMUNOL 0(0):070806191640002. [CrossRef]

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Paul J. Tacken, I. Jolanda M. De vries, Ruurd Torensma, Carl G. Figdor
Nat Rev Immunol 7(10):790. [CrossRef]

The potential of exosomes in immunotherapy
Nathalie Chaput, Julien Taïeb, Fabrice André, Laurence Zitvogel
ebot 5(6):737. [CrossRef]

Targeting allergen to FcγRI: a strategy to treat allergic disease?
Kathryn E Hulse, Judith A Woodfolk
8(6):547. [CrossRef]